Amneal Pharmaceuticals Inc Class A (AMRX) Key Ratios
$21.23
As on 20-Nov-2026 12:36EST
Market cap
$7,449 Mln
Revenue (TTM)
$3,196 Mln
P/E Ratio
53.5
P/B Ratio
14
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 8.35 | 9.96 | 8.88 | 10.22 | 9.11 |
| EBIT | -49.33 | 28.44 | 50.49 | 26.62 | 21.50 |
| Net Profit | -190.70 | -209.52 | 255.71 | 49.82 | 28.58 |
| EPS | -112.64 | -404.43 | 3,081.78 | 92.37 | 37.71 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| 10.41 | 9.65 | 14.84 | 12.60 | 7.29 |
| Net Margin
| -- | -2.68 | 4.62 | -- | -- |
| Return on equity
| 42.80 | 18.43 | -- | -80.04 | 261.24 |
| Return on Capital
| -1.50 | -1.65 | -- | 2.80 | -4.45 |
| Return on Assets
| -1.22 | -1.35 | 2.72 | 2.01 | -3.35 |
| Debt to Equity (x)
| -- | -- | 5.49 | -38.65 | -23.73 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
--
|
2.80
|
-4.45
|
-2.84
|
-4.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
--
|
-80.04
|
261.24
|
-52.79
|
-39.46
|
|
Peer Median
|
15.89
|
--
|
--
|
--
|
--
|
ROA
2.72
Higher than Peers by 0.03
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
2.72
|
2.01
|
-3.35
|
-2.31
|
-3.36
|
|
Peer Median
|
2.69
|
--
|
--
|
--
|
--
|
EBIT Margin
14.84
Higher than Peers by 1.98
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
14.84
|
12.60
|
7.29
|
11.34
|
9.04
|
|
Peer Median
|
12.86
|
--
|
--
|
--
|
--
|
Net Margin
4.62
Lower than Peers by 2.85
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
4.62
|
2.39
|
-4.18
|
-3.51
|
-5.86
|
|
Peer Median
|
7.47
|
--
|
--
|
--
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
8.88
Higher than Peers by 0.33
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
8.88
|
0.08
|
0.17
|
0.08
|
0.06
|
|
Peer Median
|
8.55
|
--
|
--
|
--
|
--
|
EBIT Growth
50.49
Higher than Peers by 42.35
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
50.49
|
86.80
|
-24.98
|
35.67
|
19.29
|
|
Peer Median
|
8.14
|
--
|
--
|
--
|
--
|
Net Profit Growth
255.71
Higher than Peers by 249.10
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
255.71
|
161.65
|
-39.16
|
35.38
|
-1,323.51
|
|
Peer Median
|
6.61
|
--
|
--
|
--
|
--
|
EPS Growth
3,081.78
Higher than Peers by 3,072.93
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
3,081.78
|
1.59
|
-0.09
|
0.60
|
-13.06
|
|
Peer Median
|
8.85
|
--
|
--
|
--
|
--
|
Book Value Growth
569.48
Higher than Peers by 564.08
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
569.48
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.40
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
5.49
Higher than Peers by 5.05
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
5.49
|
-38.65
|
-23.73
|
139.05
|
9.53
|
|
Peer Median
|
0.44
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.42
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
0.42
|
-0.30
|
-3.11
|
11.51
|
0.35
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
1.87
Higher than Peers by 0.01
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
1.87
|
2.17
|
1.41
|
1.63
|
1.88
|
|
Peer Median
|
1.86
|
--
|
--
|
--
|
--
|
Quick Ratio
1.24
Lower than Peers by 0.10
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
1.24
|
1.48
|
0.86
|
0.94
|
1.17
|
|
Peer Median
|
1.34
|
--
|
--
|
--
|
--
|
Interest Coverage
1.99
Lower than Peers by 4.16
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
1.99
|
1.58
|
0.79
|
1.29
|
1.26
|
|
Peer Median
|
6.15
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
31.88
Higher than Peers by 10.59
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
31.88
|
31.13
|
27.76
|
26.97
|
33.53
|
|
Peer Median
|
21.29
|
--
|
--
|
--
|
--
|
Asset Turnover
0.59
Higher than Peers by 0.18
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
0.59
|
0.84
|
0.80
|
0.66
|
0.57
|
|
Peer Median
|
0.41
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
--
|
103.79
|
92.91
|
105.86
|
118.59
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
--
|
118.22
|
122.93
|
132.77
|
131.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
--
|
49.91
|
41.54
|
37.06
|
38.29
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
--
|
172.10
|
174.30
|
201.57
|
211.41
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
53.45
Lower than Peers by 1.39
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
53.45
|
56.80
|
-20.99
|
-17.61
|
-2.32
|
|
Peer Median
|
54.84
|
--
|
--
|
--
|
--
|
Price / Book Value
14.02
Higher than Peers by 6.74
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
14.02
|
-57.81
|
-22.46
|
74.79
|
1.01
|
|
Peer Median
|
7.27
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
16.56
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
16.56
|
10.79
|
11.22
|
8.26
|
7.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
7,449
Higher than Peers by 5,924
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Amneal Pharmaceuticals Inc Class A (AMRX)
|
7,449
|
--
|
--
|
--
|
--
|
|
Peer Median
|
1,525
|
--
|
--
|
--
|
--
|